| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Definium Therapeutics Inc Com | LSD | Cluster Headache | Phase 2a | Ongoing | Oral | Neurology |
| Definium Therapeutics Inc Com | MM120 - (Panorama) | Generalized Anxiety Disorder (GAD) | Phase 3 | Ongoing | Oral | Psychiatric |
| Definium Therapeutics Inc Com | MM-110 (18-MC) | Opioid Withdrawal | Phase 2a | Trial Planned | Oral | Anti-Addiction |
| Definium Therapeutics Inc Com | LSD | Cluster Headache | Phase 2a | Ongoing | Oral | Neurology |
| Definium Therapeutics Inc Com | MM-120 (LSD) | Generalized Anxiety Disorder (GAD) | Phase 2b | Data Released | Oral | Psychiatric |
| Definium Therapeutics Inc Com | MM-110 (18-MC) | Opioid Withdrawal | Phase 2a | Trial Planned | Oral | Anti-Addiction |
| Definium Therapeutics Inc Com | MM120 - (Voyage) | Generalized Anxiety Disorder (GAD) | Phase 3 | Trial Planned | oral | Psychiatric |
| Delcath Systems Inc. | HEPZATO | Liver-Dominant Metastatic Colorectal Cancer | Phase 2 | Enrollment Initiation | Intra-arterial | Oncology |